Background {#Sec1}
==========

Alzheimer's disease (AD) is a neurodegenerative disease characterized by substantial memory impairment, aphasia, apraxia, agnosia and function disturbance \[[@CR1]\]. AD is the most common cause of dementia in older people and accounts for 60--80 % of reported dementia cases in the World \[[@CR2]\]. Although psychosocial and pharmacologic interventions can be effective for alleviating AD-related symptoms \[[@CR3]\], there is currently no curative treatment for AD.

It has been reported that some Chinese herbs may protect brain cells against AD \[[@CR4], [@CR5]\]. However, clinical evidence regarding the efficacy of Chinese medicine (CM) for treating AD is limited. This study therefore aims to investigate the extent to which CM is used by patients suffering from AD, and to identify the most common Chinese herbal formulae used by AD patients to treat their symptoms.

Methods {#Sec2}
=======

This study was approved by the Taipei City Hospital Institutional Review Board under study number TCHIRB-1020816-E (Additional file [1](#MOESM1){ref-type="media"}) and National Health Research Institutes under study number NHIRD-103-091 (Additional file [2](#MOESM2){ref-type="media"}). The research and associated reporting have been conducted in accordance with conventional ethical principles to protect the identities of the patients involved.

Data resources {#Sec3}
--------------

This retrospective, nationwide, population-based cohort study was conducted using a randomly sampled cohort of one million patients, selected from the National Health Insurance Research Database (NHIRD) between 1997 and 2008 in Taiwan. The National Health Insurance (NHI) system covers over 97 % of the population of Taiwan and provides full reimbursement to its members for treatments based on CM, including Chinese herbal products, acupuncture, moxibustion and traumatology manipulative therapies. The NHI also holds all of the medical records for CM treatments prescribed by licensed CM practitioners \[[@CR6]\].

One million patient records were randomly selected from those of the 23 million Taiwanese people currently insured under the NHI system. No significant differences were observed in the demographic distribution between the random sample and the original NHIRD. The medical records used in this study were collected for the dates between the 1st of January, 1996 and the 31st of December, 2008. The NHIRD database contained complete data pertaining to clinical visits, and hospitalization records, including visit date, hospital, physician specialist, major diagnoses and the dosage and frequency of any medicines prescribed. The Bureau of National Health Insurance requires physicians to record major diagnoses according to the format described in the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

Study sample {#Sec4}
------------

Figure [1](#Fig1){ref-type="fig"} shows a flowchart describing of the sample selection process. First, all patients without dementia (ICD-9 codes: 290.0, 290.1, 290.2, 290.3, 290.4, 294.1, 294.2 and 331) were excluded (n = 965,572). Second, we excluded patients with a dementia diagnosis not made by a qualified neurologist or psychologist (n = 13,403), along with patients that did not receive anti-AD treatment (n = 19,822). Doctors in Taiwan are requested by the Bureau of National Health Insurance to only prescribe anti-AD drugs to patients that fulfill the criteria outlined by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS), the Alzheimer's Disease and Related Disorders Association (ADRDA) or the Diagnostic and Statistical Manual of Mental Disorders (DSM IV-TR). Finally, cases of AD diagnosed before the end of 1996 were excluded from the current study, as well as those without complete NHI reimbursement data (n = 66) to ensure that all of the patients represented newly diagnosed cases of AD. Upon completion of this exclusion process, we had a study cohort consisting of 1137 patients.Fig. 1Flow chart detailing the recruitment of subjects from random sample of one million patients from the NHIRD between 1997 and 2008

Study variables {#Sec5}
---------------

Several demographic factors were selected from previous studies \[[@CR7]\]. The patients were categorized into six different age groups: \<45, 45--54, 55--64, 65--74, 75--84 and ≥85 years of age. The geographic locations of the patients were sorted into seven different regions with similar regional environments: Taipei City and Kaohsiung City, the Northern, Central, Eastern and Southern regions of Taiwan, and the outlying islands.

The amount of money to which each patient was insured was divided into four levels: 0, 1--19,999, 20,000--39,999 and \>40,000 new Taiwanese dollars. The "0" insured level included unemployed and retired patients, for whom the insurance costs were covered by the government or other family members.

The NHIRD database was searched for diagnosis and treatment records relating to the behavioral and psychological symptoms of dementia (BPSD), including delirium (ICD9 codes: 290.11, 290.3 and 290.41), delusions (ICD9 codes: 290.20, 290.12 and 290.42), depression (ICD9 codes: 290.13, 290.21 and 290.43), sleep disturbances (ICD9 codes: 780.5 and 307.4), hallucination (ICD9 codes: 7801, 2913 and 2928) and behavioral disturbances (ICD9 codes: 294.11 and 294.21). The reimbursement database contains all of the important details relating to the prescription of conventional medicines for treating AD. The types of prescription drugs used to treat AD were categorized as follows: donepezil, rivastigmine, galantamine, memantine, deprenyl, antipsychotic, antimanic, anxiolytic and antidepressant.

The comorbidities of the patients were categorized using the icd-9-cm codes. Notably, the results of previous studies have shown that some comorbidities, including diabetes mellitus (icd9 codes: 249 and 250), hypertension (icd9 codes: 401--405), hyperlipidemia (icd9 codes: 272), chronic kidney disease (icd9 codes: 585, 586 and 588), cerebral vascular accident (icd9 codes: 430--438) and atherosclerosis (icd9 codes: 440), can affect the prognosis and treatment of patients diagnosed with AD.

Chinese medicine treatment {#Sec6}
--------------------------

Chinese herbal products (CHPs) composed of one or more herbs (i.e., herbal formulae), which are covered by the NHI system, are more widely adopted by Taiwanese patients than any other form of CM. \[[@CR8]\] Information pertaining to CHPs was obtained from the Department of Chinese Medicine and Pharmacy (DCMP), Ministry of Health and Welfare, Taiwan, including the name and ingredients of their herbal formula, as well as their pharmaceutical effects, DCMP manufacturing code and manufacturer. CHPs with the same good manufacturing practices and DCMP standards were sorted into the same group \[[@CR9]\]. The acupuncture therapy including acupoint and frequency and massage manipulation and treatment position were also record by the NHI system.

Statistical analysis {#Sec7}
--------------------

The factors associated with the CM treatments used in the current study were analyzed using multiple logistic regression with a significance level of α = 0.05. An odds ratio was used to quantify the relationships between the different conditions and CM use. All of the odds ratios were adjusted based on the demographic factors described above. Version 9.3 of the SAS statistical analysis software (version 9.4; SAS Institute Inc., Cary, NC, USA) was used for data management and analysis.

Results {#Sec8}
=======

The NHIRD of outpatient claims contained information pertaining to the claims of 1137 patients with AD from 1997 to 2008. Among them, 889 (78.2 %) AD patients used CM outpatient services. The mean age of non-CM users was slightly higher than that of CM users.

Table [1](#Tab1){ref-type="table"} shows details concerning the demographic and medication distributions of the CM and non-CM users. After adjusting for demographic factors, the results clearly showed that AD patients suffering from one or more BPSD (one symptom: OR = 0.90, 95 % CI 0.57--1.44; two symptoms: OR = 1.94, 95 % CI 1.24--3.05; three or more symptoms: OR = 2.26, 95 % CI 1.48--3.43) were more likely to seek CM treatment than those with no BPSD. Female patients and those living in urban areas were more likely to seek CM treatment than male patients and those living in rural areas. No discernible difference was observed in CM use between AD patients suffering from one or more comorbidities (one: OR = 1.1, 95 % CI 0.47--2.58; two: OR = 0.91, 95 % CI 0.41--2.01; and three or more types: OR = 1.76, 95 % CI 0.83--3.74) and those with no comorbidity.Table 1Demographic and medication characteristics and results of multiple logistic regression for CM use among patients with Alzheimer's diseaseCharacteristicsCM^a^ usersCM^a^ non-usersaOR^b^ (95 % CI^c^)No. of cases889 (78.2 %)248 (21.8 %)Age at diagnosis (incidence rate) \<45 (0.001 %)7 (0.8 %)2 (0.8 %)0.78 (0.15--4.05) 45--54 (0.036 %)27 (3 %)2 (0.8 %)3.64 (0.80--16.53) 55--64 (0.246 %)115 (12.9 %)27 (10.9 %)1 65--74 (1.185 %)309 (34.8 %)92 (37.1 %)0.74 (0.45--1.22) 75--84 (7.105 %)381 (42.9 %)107 (43.1 %)0.83 (0.51--1.36) ≥85 (17.942 %)50 (5.6 %)18 (7.3 %)0.61 (0.30--1.24)Mean years72.873.8Sex Female (0.13 %)530 (59.6 %)121(48.8 %)1.57 (1.16--2.13) Male (0.10 %)359 (40.4 %)127 (51.2 %)1Insured region Taipei city137 (15.4 %)61 (24.6 %)1 Kaohsiung city71 (8 %)14 (5.6 %)2.38 (1.24--4.57) Northern Taiwan200 (22.5 %)58 (23.4 %)1.65 (1.07--2.54) Middle Taiwan209 (23.5 %)32 (12.9 %)3.00 (1.83--4.90) Southern Taiwan240 (27 %)78 (31.5 %)1.39 (0.91--2.12) Eastern Taiwan21 (2.4 %)4 (1.6 %)2.48 (0.80--7.64) Outlying island11 (1.2 %)1 (0.4 %)4.98 (0.61--40.51)Insured amount (NT\$^d^) 0353 (39.7 %)94 (37.9 %)0.99 (0.68--1.45) 1--19,999486 (54.7 %)140 (56.5 %)1 20,000--39,99932 (3.6 %)8 (3.2 %)0.90 (0.38--2.15) ≥400,00018 (2 %)6 (2.4 %)0.77 (0.28--2.13)Numbers of anti-Alzheimer's or BPSD drugs 128 (3.1 %)8 (3.2 %)1 2145 (16.3 %)51 (20.6 %)0.81 (0.35--1.90) 3318 (35.8 %)87 (35.1 %)1.04 (0.46--2.37) ≥4398 (44.8 %)102 (41.1 %)1.12 (0.49--2.52)Numbers of dementia BPSD^e^ 0102 (11.5 %)46 (18.5 %)1 1122 (13.7 %)61 (24.6 %)0.90 (0.57--1.44)  Delirium43  Delusions137  Depression1812  Behavioral disturbance42  Sleep disturbances8337  Hallucination00 2250 (28.1 %)58 (23.4 %)1.94 (1.24--3.05)  Delirium + delusions87  Delirium + depression21  Delirium + behavioral00  Delirium + sleep126  Delirium + hallucination00  Delusions + depression106  Delusions + behavioral00  Delusions + sleep2111  Delusions + hallucination00  Depression + behavioral10  Depression + sleep218  Depression + hallucination01  Behavioral + sleep60  Behavioral + hallucination00  Sleep + hallucination16922 ≥3415 (46.7 %)83 (33.5 %)2.26 (1.48--3.43)Numbers of comorbidity 025 (2.81 %)10 (4.03 %)1 174 (8.32 %)27 (10.89 %)1.1 (0.47--2.58) 2148 (16.7 %)65 (26.21 %)0.91 (0.41--2.01) ≥3642 (72.2 %)146 (58.87 %)1.76 (0.83--3.74)^a^ CM refers to Chinese medicine^b^ aOR refers to adjust odds ratio^c^ CI refers to confidence interval^d^ NT\$ refers to new Taiwan dollars, of which 1 US \$ = 30 NT\$^e^ BPSD refers to behavioral and psychological symptoms of dementia

Analyses of the major disease categories for all CM visits are summarized in Table [2](#Tab2){ref-type="table"}. These results show that 18,138 (73.3 %) visits were treated with prescribed CHPs, whereas the remaining visits were treated with acupuncture and traumatology manipulative therapies. AD patients tended to use CHPs rather than acupuncture. "Symptoms, signs and ill-defined conditions" was cited as the most common reason for using CM (20.2 %, 5011 visits), followed sequentially by "diseases of the musculoskeletal system and connective tissue" (20.0 %, 4962 visits), "diseases of the respiratory system" (14.3 %, 3542 visits) and "diseases of the digestive system" (12.2 %, 3024 visits). Of the AD patients evaluated in the current study, 9.3 % sought CMs with the aim of treating their "mental disorders, diseases of the nervous system and sense organs".Table 2Frequency distribution of Chinese medicine visits by major disease categories (according to 9th ICD codes) in Alzheimer's patients from 1997 to 2008 in TaiwanMajor disease categoryICD-9-CM code rangeNumber of visits (%)Chinese herbal remediesAcupuncture, or manipulative therapiesTotal of CMInfectious and parasitic diseases001--13942 (0.2)5 (0.02)47 (0.2)Neoplasms140--239119 (0.5)0 (0)119 (0.5)Endocrine, nutritional, blood and metabolic diseases, and immunity disorders240--289799 (3.2)25 (0.1)824 (3.3)Mental disorders, diseases of the nervous system and sense organs290--3891901 (7.7)389 (1.6)2290 (9.3)Diseases of the circulatory system390--4591006 (4.1)162 (0.7)1168 (4.7)Diseases of the respiratory system460--5193449 (13.9)93 (0.4)3542 (14.3)Diseases of the digestive system520--5792954 (11.9)70 (0.3)3024 (12.2)Diseases of the genitourinary system580--677789 (3.2)40 (0.2)829 (3.3)Diseases of the skin and subcutaneous tissue680--709327 (1.3)9 (0.04)336 (1.4)Diseases of the musculoskeletal system and connective tissue710--7392016 (8.1)2946 (11.9)4962 (20.0)Symptoms, signs, and ill-defined conditions780--7993877 (15.7)1134 (4.6)5011 (20.2)Injury and poisoning800--99977 (0.3)852 (3.4)929 (3.8)Supplementary classificationV01--V82, E800--E9990 (0)4 (0.02)4 (0.02)Others^a^322 (1.3)848 (3.4)1170 (4.7)Total18,138 (73.3)6613 (26.7)24,751 (100.0)^a^ Other includes ICD-9-CM code range 740--779 and missing/error data

Table [3](#Tab3){ref-type="table"} shows the details of the CHPs most frequently prescribed by CM practitioners for treating mental disorders and diseases of the nervous system. The results show that *Bu*-*Zhong*-*Yi*-*Qi*-*Tang* was the most frequently prescribed CHP, followed by *Ji*-*Sheng*-*Shen*-*Qi*-*Wan*, *Ma*-*Zi*-*Ren*-*Wan* and *Tian*-*Wang*-*Bu*-*Xin*-*Dan*. The potential effects of the herbs contained in the 10 most common formulae are shown in Table [4](#Tab4){ref-type="table"}. It is noteworthy that several herbs, including *Ginseng Radix(Ren*-*Shen)* and *Angelicae Sinensis Radix Integra(Dang*-*Gui)*, appeared repeatedly in formulae reported to be effective against AD. Table [5](#Tab5){ref-type="table"} shows that 77.1 % of the AD patients consumed *Bu*-*Zhong*-*Yi*-*Qi*-*Tang* during the period covered by the current study. After adjusting for demographic factors, the results revealed that female AD patients (OR = 1.23, 95 % CI 1.04--1.57) were more likely to consume *Bu*-*Zhong*-*Yi*-*Qi*-*Tang* than male patients.Table 3Ten most commonly used herbal formulae prescribed by CM practitioners for treating mental disorders, diseases of the nervous system and sense organs (total prescriptions: 1901)Herbal formulaeEnglish nameAverage formulae dose (g/day)*Ren*-*Shen* CHF dose (g/day)*Ren*-*Shen* herbs (g/day)*Dang*-*Qui* CHF dose (g/day)*Dang*-*Qui* herbs (g/day)Frequency of prescriptions (%)*Bu*-*Zhong*-*Yi*-*Qi*-*Tang*Center-supplementing Qi-boosting decoction5.31.48.00.95.6629 (33.1)*Ji*-*Sheng*-*Shen*-*Qi*-*Wan*Life saver kidney Qi Pill5.1--------538 (28.3)*Ma*-*Zi*-*Ren*-*Wan*Cannabis fruit pill4.8--------511 (26.9)*Tian*-*Wang*-*Bu*-*Xin*-*Dan*Celestial emperor heart-supplementing elixir4.20.74.01.38.1476 (25)*Gan*-*Mai*-*Da*-*Zao*-*Tang*Licorice, wheat, and jujube decoction3.9--------421 (22.1)*Sheng*-*Mai*-*San*Pulse-engendering powder2.61.58.6----396 (20.8)*Tian*-*Ma*-*Gou*-*Teng*-*Yin*Gastrodia and uncaria beverage5.5--------381 (20)*Liu*-*Wei*-*Di*-*Huang*-*Wan*Six-ingredient rehmannia pill2.1--------336 (17.7)*Qi*-*Bao*-*Mei*-*Ran*-*Dan*Seven-jewel beard-blackening elixir3.5----0.95.6284 (14.9)*Tao*-*Hong*-*Si*-*Wu*-*Tang*Peach Kernel and Carthamus four agents decoction2.2----0.42.5258 (13.6)Table 4Potential effects of the herbs contained in the ten most common formulae prescribed by CM practitioners for treating Alzheimer's diseaseHerbal formulaeConstituents*Bu*-*Zhong*-*Yi*-*Qi*-*Tang* ^a,\ b,\ c,\ d^*Astragali Radix Cruda (Huang*-*qi),Ginseng Radix (Ren*-*shen)* ^a,\ b,\ c,\ d^ *, Glycyrrhizae Radix cum Liquido Fricta (Zhi*-*gan*-*cao), Atractylodis MacrocephalaeRhizoma (Bai*-*zhu), Angelicae Sinensis Radix Integra (Dang*-*gui)* ^a,\ c,\ d^ *, CitriReticulatae Pericarpium (Chen*-*pi), Cimicifugae Rhizoma (Sheng*-*ma), Bupleuri Radix (Chai*-*hu), Zingiberis Rhizoma Recens (Sheng*-*jiang), Jujubae Fructus (Da*-*zao)Ji*-*Sheng*-*Shen*-*Qi*-*Wan* ^a,\ c^*Rehmanniae Radix (Di*-*huang), Poria cum (Fu*-*ling)* ^a,\ c^ *, Corni Fructus (Shan*-*zhu*-*yu), Dioscoreae Rhizoma (Shan*-*yao), Moutan Cortex (Mu*-*dan*-*pi), Alismatis Rhizoma (Ze*-*xie), Aconiti Radix Lateralis (Fu*-*zi), Cinnamomi Cortex (Rrou*-*gui), Achyranthis Bidentatae Radix (Huai*-*niu*-*xi), Plantaginis Semen (Che*-*qian*-*zi)Ma*-*Zi*-*Ren*-*Wan* ^a,\ c^*Cannabis Fructus (Ma*-*zi*-*ren), Rhei Radix et Rhizoma (Da*-*huang)* ^c^ *, Paeoniae Radix Alba (Bai*-*shao)* ^a^ *, Aurantii Fructus Immaturus (Zhi*-*shi), Magnoliae Officinalis Cortex (Hou*-*po), Armeniacae Semen (Xing*-*ren)Tian*-*Wang*-*Bu*-*Xin*-*Dan* ^a,\ b,\ c,\ d^*Rehmanniae Radix (Di*-*huang), Ginseng Radix (Ren*-*shen)* ^a,\ b,\ c,\ d^ *, Polygalae Radix (Yuan*-*zhi)* ^c^ *, Scrophulariae Radix(Xuan*-*shen), Platycladi Semen (Bai*-*zi*-*ren), Platycodonis Radix (Jie*-*geng), Asparagi Radix (Tian*-*men*-*dong), Salviae Miltiorrhizae Radix (Dan*-*shen)* ^c^ *, Ziziphi Spinosi Semen (Suan*-*zao*-*ren), Ophiopogonis Radix (Mai*-*men*-*dong), Poria cum PiniRadice (Fu*-*shen)* ^a,\ c^ *, Angelicae Sinensis Radix Integra (Dang*-*gui)* ^a,\ c,\ d^ *, Schisandrae Fructus (Wu*-*wei*-*zi)Gan*-*Mai*-*Da*-*Zao*-*TangGlycyrrhizae Radix Cruda (Zhi*-*gan*-*cao),Jujubae Fructus (Da*-*zao), Tritici Semen (Xiao*-*mai)Sheng*-*Mai*-*San* ^a,\ b,\ c,\ d^*Ginseng Radix (Ren*-*shen)* ^a,\ b,\ c,\ d^ *,Ophiopogonis Radix (Mai*-*men*-*dong), Schisandrae Fructus (Wu*-*wei*-*zi)Tian*-*Ma*-*Gou*-*Teng*-*Yin* ^a,\ c^*Gastrodiae Rhizoma (Tian*-*ma)* ^c^ *, Uncariae Ramulus cum Uncis (Gou*-*teng)* ^a^ *, Haliotidis Concha (Shi*-*jue*-*ming), Gardeniae Fructus(Shan*-*zhi*-*zi), Scutellariae Radix (Huang*-*qin), Eucommiae Cortex (Du*-*zhong), Loranthiseu Visci Ramus (Sang*-*ji*-*sheng), LeonuriHerba (Yi*-*mu*-*cao), PolygoniMultiflori Caulis (Ye*-*jiao*-*teng), Achyranthis Bidentatae Radix (Huai*-*niu*-*xi), Poria cum Pini Radice (Fu*-*shen)* ^a,\ c^*Liu*-*Wei*-*Di*-*Huang*-*Wan* ^c^*Rehmanniae Radix (Di*-*huang), Poria cum (Fu*-*ling)* ^c^ *, CorniFructus (Shan*-*zhu*-*yu), DioscoreaeRhizoma (Shan*-*yao), Moutan Cortex (Mu*-*dan*-*pi), AlismatisRhizoma (Ze*-*xie)Qi*-*Bao*-*Mei*-*Ran*-*Dan* ^a,\ c,\ d^*PolygoniMultiflori Radix (He*-*shou*-*wu), AchyranthisBidentatae Radix (Huai*-*niu*-*xi), AngelicaeSinensis Radix Integra (Dang*-*gui)* ^a,\ c,\ d^ *, Poria cum (Fu*-*ling), Cuscutae Semen (Tu*-*si*-*zi), LyciiFructus (Gou*-*qi*-*zi), PsoraleaeFructus (Po*-*gu*-*zhi)Tao*-*Hong*-*Si*-*Wu*-*Tang* ^a,\ c,\ d^*Persicae Semen (Yao*-*ren), Carthamustinctorius Flos (Hong*-*hua), Angelicae Sinensis Radix Integra (Dang*-*gui)* ^a,\ c,\ d^ *, Chuanxiong Rhizoma (Chuan*-*xiong), Paeoniae Radix Alba (Bai*-*shao)* ^a^ *, Rehmanniae Radix (Di*-*huang)*^a^ Formula containing a single herb that might promote the neurotransmitter acetylcholine^b^ Formula containing a single herb that might inhibit the *N*-methyl-D-aspartate (NMDA) receptor^c^ Formula containing a single herb that might reduce the *β*-amyloid^d^ Formulae containing a single herb that might decrease the Tau proteinTable 5Demographic characteristics of *Bu*--*Zhong*--*Yi*--*Qi*--*Tang* use among patients with Alzheimer's diseaseCharacteristics*Bu*--*Zhong*--*Yi*--*Qi*--*Tang* users (%)CM^a^ users not using *Bu*--*Zhong*--*Yi*--*Qi*--*Tang* (%)aOR^b^ (95 % CI^c^)No. of cases685 (77.1)204 (22.9)Age at diagnosis \<455 (0.7)2 (1)0.69 (0.12--6.03) 45--5421 (3.1)2 (1)3.17 (0.70--17.44) 55--6488 (12.8)22 (10.8)1 65--74221 (32.1)70 (34.3)0.72 (0.23--1.34) 75--84304 (44.1)92 (45.1)0.92 (0.41--1.52) ≥8545 (6.5)16 (7.8)0.64 (0.22--1.59)Sex Female377 (55.0)99 (48.5)1.23 (1.04--1.57) Male308 (45.0)104 (51.0)1Numbers of anti--Alzheimer's or BPSD drugs 126 (3.8)11 (5.4)1 2133 (19.4)55 (27.0)0.82 (0.21--2.01) 3259 (37.8)75 (36.8)1.32 (0.52--2.81) ≥4367 (39.0)63 (40.9)1.04 (0.57--2.11)Numbers of dementia BPSD^d^ 084 (12.3)42 (20.6)1 1115 (16.8)63 (30.9)0.72 (0.31--1.68) 2206 (30.1)52 (25.5)2.11 (0.93--3.38) ≥3280 (40.9)63 (30.9)2.75 (0.82--4.31)Numbers of comorbidity 022 (3.2)12 (5.9)1 190 (13.1)35 (17.2)1.21 (0.38--3.71) 2119 (17.4)57 (27.9)1.02 (0.31--4.23) ≥3454 (66.3)99 (48.5)2.24 (0.71--4.55)^a^ CM refers to traditional Chinese medicine^b^ aOR refers to adjust odds ratio^c^ CI refers to confidence interval^d^ BPSD refers to behavioral and psychological symptoms of dementia

Discussion {#Sec9}
==========

To the best of our knowledge, this study was the first reported one using a random national-level sample to document the usage characteristics of traditional Chinese medicines in AD patients. The incidence of AD was less than 0.3 % in people aged 55--64 years, with the incidence increasing with increasing age. In people aged 85 years or older, the incidence was found to be 17.9 %, which is low compared with results of previous surveys \[[@CR10], [@CR11]\]. Notably, all of the patients described in the current study were newly diagnosed with AD by board-certified neurologists or psychiatrists and selected from a random sample of one million patients. Furthermore, these patients were selected from the insured general population of Taiwan and the rate of insured people was consistently above 97 % since 1997. The possibility of selection or recall bias could therefore be excluded.

More than 78 % of the AD patients in the cohort were used some form of CM during the 12 years covered by the current study. High accessibility and full coverage for CM through the NHI scheme in Taiwan could lead to an increase in CM use. Furthermore, several Chinese herbs may be effective as alternative therapies for treating AD and related disorders \[[@CR12]\]. The current findings also show that women and those living in urban areas are more likely to use CM than men and patients living rural areas. Similar trends were reported previously \[[@CR13]\].

BPSD relating to AD such as delusions, paranoia, hallucinations and anxiety could lead to an increase in caregiver burden and accelerate the progression of AD \[[@CR14]\]. AD patients suffering from one or more BPSD were more likely to use traditional CM than those with no BPSD. In addition, using anti-AD or BPSD drugs did not lead to a reduction in CM use. AD patients consumed herbal therapies with the aim of relieving their AD-related symptoms, rather than using these treatments as alternatives to standard anti-AD treatments (i.e., herbal therapies were consumed as complementary medicines).

The category "symptoms, signs and ill-defined conditions" was the most frequently cited diagnosis in the disease category for CM visits to classify the diagnosis pattern of CM. This phenomenon has also been observed in several other patient populations \[[@CR15]\]. In addition, 9.3 % of patients with AD in the "mental disorders, diseases of the nervous system and sense organs" disease category had specifically sought out CM to treat their condition. CM treatments were generally used as adjuvant therapies to relieve AD-related symptoms rather than being used as replacements for conventional anti-AD treatment.

The category "diseases of the digestive system" was cited as one of the most common reasons for using CHPs (11.9 %, 2954 visits), with *Ma*-*Zi*-*Ren*-*Wan* being used to treat constipation \[[@CR16]\]. Constipation is a common problem among geriatric patients, especially those with AD, in whom it is generally exacerbated by a lack of exercise or the side effects of anti-AD drugs \[[@CR17]\]. Severe constipation in AD patients can lead to confusion and symptoms of irritability or aggression because of the pain and discomfort associated with this condition \[[@CR18]\]. Moreover, emodin, which is the major chemical constituent of *Ma*-*Zi*-*Ren*-*Wan*, protects the cortical neurons from *β*-amyloid-induced toxicity, representing a possible mechanism for treating AD \[[@CR19]\]. In this study, *Bu*-*Zhong*-*Yi*-*Qi*-*Tang* was determined to be the most commonly prescribed formula, especially for female AD patients. *Bu*-*Zhong*-*Yi*-*Qi*-*Tang* led to elevated levels of dopamine and noradrenaline in the cortical tissues of mice, as well as improved attention, learning function and memory \[[@CR20], [@CR21]\]. *Bu*-*Zhong*-*Yi*-*Qi*-*Tang* was also used to treat elderly patients with weakness and fatigue \[[@CR22]\].

Some frequently prescribed formulae have been reported to exhibit potentially positive effects on AD. For example, *Sheng*-*Mai*-*San* was reported to improve memory and decrease neuronal apoptosis in the hippocampus \[[@CR23]\]. Furthermore, *Ji*-*Sheng*-*Shen*-*Qi*-*Wan* and *Liu*-*Wei*-*Di*-*Huang*-*Wan*, which both belong to the *Di*-*Huang*-*Wan* group of formulae and share similar herbal components, were reported to increase cognitive function after 2 months of treatment \[[@CR24]\]. Some formulae were reported to show neuroprotective activity. For example, *Tian*-*Ma*-*Gou*-*Teng*-*Yin* led to a reduction in necrosis and apoptosis in neuronal cells through a variety of pharmacological effects, including anti-inflammatory, antioxidative and antiapoptotic activities \[[@CR25]\]. *Tao*-*Hong*-*Si*-*Wu*-*Tang* exhibited neuroprotective effects against focal cerebral ischemia. Moreover, *Gan*-*Mai*-*Da*-*Zao*-*Tang* exhibited sedative and anti-anxiety effects in an animal model \[[@CR26]\]. All of the aforementioned formulae, which are standard formulae recommended by the DCMP, Ministry of Health and Welfare, Taiwan, must be modified by qualified CM practitioners in accordance with the principle of syndrome pattern identification as the basis for determining treatment.

Table [4](#Tab4){ref-type="table"} lists all of the herbs contained in the top ten most frequently prescribed formulae. *Ginseng Radix* (*Ren*-*Shen*), which is the major constituent herb in three of the top ten formulae, has been reported to show multiple effects against AD-related factors such as decreasing *β*-amyloid formation \[[@CR27]\], increasing choline acetyltransferase \[[@CR28]\] and forming a competitive interaction with the *N*-methyl-*D*-aspartate receptor \[[@CR29]\]. *Ginseng Radix* has also been reported to increase cognitive function \[[@CR30]\]. *Angelicae Sinensis Radix Integra* (*Dang*-*Gui*) is the key component of *Bu*-*Zhong*-*Yi*-*Qi*-*Tang*, *Tian*-*Wang*-*Bu*-*Xin*-*Dan* and *Tao*-*Hong*-*Si*-*Wu*-*Tang*. An ethanolic extract of *Dang*-*Gui* enhanced cholinergic function \[[@CR31]\], inhibited acetylcholinesterase \[[@CR32]\], reduced *β*-amyloid associated neurotoxicity and decreased Tau protein hyperphosphorylation in a dose-dependent manner \[[@CR33]\].

There were several limitations associated with the current study. First, health foods containing herbs, folk medicines and prescriptions from CM practitioners without a license from the Taiwanese authorities were not included in this study. Therefore CHP use may have therefore been underestimated. However, high healthcare insurance coverage and low prices of government-approved CM led to a reduction in herbal folk medicine use. Second, it is not possible to draw any conclusions regarding the relationship between cognitive function and CM use because of a general lack of detailed clinical data. This study focused primarily on a patient population with AD, the AD diagnosis was rigorously censored by the Bureau of National Health Insurance. Third, this study was conducted retrospectively and did not include a randomized placebo group. Lastly, the CM formulae were modified according to the principle of syndrome differentiation.

Conclusions {#Sec10}
===========

Most people with AD who consumed herbal products used supplement *qi*, nourish the *blood*, and quiet the heart spirit therapy as complementary medicines to relieve AD-related symptoms, in addition to using standard anti-AD treatments.
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